Aurora CO 软组织肉瘤临床试验
9项针对 软组织肉瘤的研究正在 Aurora及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
招募中1/2 期
- University of Colorado Denver, Aurora
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
招募中1 期
- University of Colorado Hospital, Aurora
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
招募中1 期
- UCHealth University of Colorado Hospital, Aurora
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
招募中1 期
- Children's Hospital Colorado, Aurora
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
招募中1/2 期
- Children's Hospital Colorado, Aurora
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
招募中2 期
- University Of Colorado Hospital, Aurora
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
招募中2 期
- Children's Hospital of Colorado, Aurora
其他城市的 软组织肉瘤试验
- Houston, TX32 项研究
- New York City, NY20 项研究
- Boston, MA18 项研究
- St. Louis, MO14 项研究
- Los Angeles, CA13 项研究
- Columbus, OH13 项研究
- Washington, DC12 项研究
- Memphis, TN11 项研究
- Philadelphia, PA10 项研究
- Queens, NY9 项研究
- Rochester, MN9 项研究
- Nashville, TN9 项研究
Aurora的其他研究
- 癌症（所有类型）35 项研究
- 结直肠癌32 项研究
- 非小细胞肺癌30 项研究
- 乳腺癌26 项研究
- 转移性癌症25 项研究
- 卵巢癌24 项研究
- 1型糖尿病23 项研究
- 肥胖症21 项研究
- 肺癌19 项研究
- 黑色素瘤18 项研究
- 心力衰竭18 项研究
- 前列腺癌17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。